Patients with acute myocardial infarction (AMI) who undergo percutaneous coronary intervention (PCI) and receive intensive evolocumab therapy have lower low-density lipoprotein cholesterol (LDL-C) levels compared with patients who only receive standard care, late-breaking trial data show.